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Original Article

Stereotactic body radiation therapy (SBRT) for patients with stage
I non-small cell lung cancer is applicable to more tumors than
sublobar resection
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Background: Virtually all patients with medically inoperable stage I non-small cell lung cancer (NSCLC)
can receive stereotactic body radiation therapy. However, the percentage of such patients in whom sublobar
resection is technically feasible is unknown. This discrepancy can confound clinical trial eligibility and
designs comparing stereotactic body radiation therapy vs. sublobar resection.
Methods: A total of 137 patients treated with stereotactic body radiation therapy for lung lesions (3/2013–
11/2017) underwent retrospective review. Diagnostic CT chest and PET/CT images, stereotactic body
radiation therapy dates, and demographic data were collected on 100 of 137 patients. Two experienced boardcertified thoracic surgeons independently reviewed anonymized patients’ pre-stereotactic body radiation
therapy diagnostic imaging and completed a custom survey about the technical feasibility of sublobar
resection for each patient. Interrater agreement was measured using Cohen’s kappa coefficient by bootstrap
methodology. Summary statistics were performed for baseline demographics and tumor characteristics.
Results: Of the 100 patients, 57% were female, with median age of 75 years (range, 52–95 years) and
Karnofsky Performance Status of 80 (range, 40–100). Most patients (61%) had Stage IA1, T1a tumors. For
interrater agreement analysis, one patient was removed from each cohort due to inability to locate tumor on
images, leaving 98 patients analyzed. Comparing Surgeon #1 vs. Surgeon #2, 64 (65.3%) vs. 69 (70.3%) of
tumors were thought eligible for sublobar resection, respectively (κ=0.414).
Conclusions: Stereotactic body radiation therapy for stage I NSCLC is applicable to more tumors than
sublobar resection, with ~30–35% of stereotactic body radiation therapy patients unable to undergo sublobar
resection assessed by pretreatment diagnostic imaging based on technical grounds. This study illustrates
that clinical trials comparing stereotactic body radiation therapy vs. sublobar resection are limited to only a
subpopulation of patients with stage I NSCLC.
Keywords: Stereotactic body radiation therapy (SBRT); stereotactic ablative radiotherapy (SAbR); sublobar
resection; wedge resection; segmentectomy; early stage non-small cell lung cancer (early stage NSCLC)
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Stereotactic body radiation therapy (SBRT), also known as
stereotactic ablative radiotherapy (SAbR), is often offered as
an alternative to surgery for early stage non-small cell lung
cancer (NSCLC) patients who are medically inoperable or
who decline surgery (1). Virtually all of these patients can
receive SBRT despite their medical shortcomings. SBRT
has been proven to have a high rate of local control (~90–
95%) with limited toxicity, even with long-term follow-up,
with the most common recurrences occurring regionally or
distantly (2). In a pooled analysis of the STARS and ROSEL
trials, which looked at operable Stage I NSCLC patients,
SBRT was found to have a higher overall survival of 95% at
3 years compared to patients who had received lobectomy
and mediastinal lymph node dissection at 75%, with similar
recurrence free survival (3). Patients who had received
surgery had more Grade 3 or higher events than the SBRT
arms (44% vs. 10%).
An ongoing phase 3 trial, STABLE-MATES, is looking
to determine if this overall survival difference will be
observed in a larger patient population, when comparing
head-to-head sublobar resection vs SBRT with 54 Gy in
3 fractions for early stage peripheral lesions (4). One of the
inclusion criteria is whether a patient’s tumor is in a location
that will allow for a sublobar resection. Sublobar resection,
performed as a wedge resection or segmentectomy, is more
akin to SBRT, with recent studies suggesting similar clinical
outcomes to lobectomy in certain contexts when accounting
for tumor size and location (5-7). This criterion raises an
interesting question. What proportion of patients eligible
for SBRT are not eligible for sublobar resection due to
technical inability to resect the tumor? To date, there is
no published literature quantifying this specific parameter
which could potentially change clinical trial design and
patient eligibility regarding these modalities in the future,
as well as specific recommendation for clinical practice
guidelines.
We report a novel assessment of early stage NSCLC
patients eligible for and treated with SBRT, but who are not
amenable to sublobar resection due to technical considerations.
We present the following article in accordance with the
STROBE reporting checklist (available at http://dx.doi.
org/10.21037/jtd-20-2001).

of Helsinki (as revised in 2013). The study was approved
by the Institutional Review Board at Thomas Jefferson
University (Philadelphia, PA; IRB Control # 17D.549) and
individual consent for this retrospective analysis was waived.
We identified 137 consecutive patients treated at our
institution with SBRT for lung lesions from March 2013
to November 2017. Of these patients, 37 patients were
removed from analysis for the following reasons: 33 patients
received SBRT for lung metastases and 4 lacked preSBRT imaging records. For the remaining 100 patients, we
collected diagnostic CT chest images, PET/CT images,
SBRT treatment details, and demographic data (Figure 1).
Staging was reported per AJCC 7th edition.
Two experienced board-certified thoracic surgeons,
with 7 and 11 years of practice and performing 80 to 100
surgeries per year for stage I NSCLC at time of study,
independently reviewed each patient’s anonymized preSBRT diagnostic CT chest scans along with corresponding
PET/CT images when available. With each patient review,
the thoracic surgeons filled out a customized survey which
was created with input from radiation oncologists and
thoracic surgeons to evaluate technical feasibility of a
sublobar resection of primary lung lesions (Figure 2). This
survey asked questions on the following:
(I) Ability to identify the lung tumor in question (yes/no);
(II) Technical feasibility of any sublobar resection (yes/no);
(III) Technical feasibility of wedge resection (yes/no);
(IV) Technical feasibility of segmentectomy (yes/no).
Surgeons were asked to provide the best answer to each
of the questions. If the surgeons answered “no” to question
#III, they were further prompted to provide reasons for not
being able to perform wedge resection including:
i.
The tumor is too deep within the lung;
ii.
Inadequate margin due to tumor size;
iii. Inadequate margin due to tumor location;
iv. The tumor is too small to be palpable;
v.
Other (free-form response).
Similarly, if the surgeons answered “no” to question #IV,
then reasons against segmentectomy included:
i.
The tumor is not clearly confined to one segment;
ii.
Inadequate margin due to tumor size;
iii. Inadequate margin due to tumor location;
iv. Segmental anatomy is not clear on imaging;
v.
Other (free-form response).

Methods

Statistical analysis

The study was conducted in accordance with the Declaration

Interrater agreement between the surgeons was measured
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Assessed for eligility (n=137)
Excluded
- Non-lung primary, metastatic lung lesions (n=33)
- Lack of pre-SBRT imaging for review (n=4)
Pre-SBRT imaging reviewed for sublobar
resection feasibility via survey (n=100)

Thoracic surgeon #1

Thoracic surgeon #2

Lesion identifiable
from imaging (n=99)
Unable to identify
lesion pre-SBRT (n=1*)

Lesion identifiable
from imaging (n=99)
Unable to identify
lesion pre-SBRT (n=1*)

Interrater analysis (n=98)

Interrater analysis (n=98)

Figure 1 CONSORT diagram. *, each surgeon was unable to identify one lesion of interest on pre-SBRT imaging for one patient. These
were different patients, so for interrater analysis, both of these patients were excluded.

using Cohen’s kappa coefficient by bootstrap methodology (8).
Kappa coefficient (κ) ranges were determined as follows (9):
κ ≤0 as indicating no agreement;
i.
ii.
0.01≥ κ ≤0.20 as none to slight;
iii.
0.21≥ κ ≤0.40 as fair;
iv.
0.41≥ κ ≤0.60 as moderate;
v.
0.61≥ κ ≤0.80 as substantial and;
vi.
0.81≥ κ ≤1.00 as almost perfect agreement.
For reasons against technical feasibility of wedge
resection (question #IV) or segmentectomy (question #VI),
we examined interrater agreement analysis for patients
where both Surgeon #1 and Surgeon #2 were in consensus
that the lesion was not amenable to wedge resection or
segmentectomy. In the event that a surgeon provided
multiple responses for a lesion, interrater analysis was
determined through partial agreement. For example, if
Surgeon #1 responds ‘i’ and Surgeon #2 responds ‘i/ii’, we
consider the second response to be ‘i’ and thus qualify as a
match to the first response. On the other hand, If Surgeon
#1 responds ‘i’ and Surgeon #2 responds ‘ii/iii’, then we
would consider the second response to be ‘ii’ (or ‘iii’) and
not qualify as a match to the first answer.
Summary statistics were performed for baseline
demographics, tumor characteristics, and surgeon-provided
reasons against sublobar resection techniques. Statistics
were analyzed with R (version 3.5.1).

© Journal of Thoracic Disease. All rights reserved.

Results
Patient demographics
Of the 100 patients, 57% were female and 43% were male.
Median age at SBRT was 75 years (range, 52–95 years)
and median KPS was 80 (range, 40–100). The majority
of patients (61%) had stage IA1, T1a tumors, followed by
stage IA2, T1b (22%), and stage IB, T2a (17%).
Individual surgeon responses
Surgeon #1 identified lesions from 99 patients for the
available pre-SBRT imaging. Surgeon #2 also identified
99 lesions from the pre-SBRT imaging. However, these
lesions were in separate patients, so after these two patients
were removed, 98 patients underwent further analysis.
According to Surgeon #1, of these 98 patients, 64 (65.3%)
were amenable to sublobar resection. Of these, 64 (100%)
had the option of wedge resection as feasible while 42
(65.6%) were considered feasible for segmentectomy. The
most common reason against wedge resection was “depth of
tumor in lung” for 22 patients (64.7%). The most common
reason against segmentectomy was “inadequate margin due
to tumor location” and “segmental anatomy not clear on
imaging”, both with 23 responses (41.1%).
For Surgeon #2, 69 (70.4%) of tumors were amenable
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1. Are you able to identify the lung tumor in question?
a. Yes
b. No

segmentectomy was different, with “tumor not clearly
confined to one segment” in 44 patients (80%). Please see
Figure 3 for detailed response breakdown.

2. Is this tumor amenable to a sublobar resection ?
a. Yes
b. No
3. If yes, can wedge resection be performed?
a. Yes
b. No
4. If not wedge, why?
a. The tumor is too deep within the lung
b. Inadequate margin due to tumor size
c. inadequate margin due to tumor location
d. The tumor is too small to be palpable
e. Other: ___fill in the blank_______
5. If yes, can segmentectomy be performed?
a. Yes
b. No
6. If not segmentectomy, why?
a. The tumor is not clearly confined to one segment
b. Inadequate margin due to tumor size
c. inadequate margin due to tumor location
d. segmental anatomy is not clear on imaging
e. Other: ___fill in the blank_______

Interrater agreement analysis
For interrater agreement analysis, one patient each was
removed from each set of surgeon responses due to a
response of “inability to identify the tumor” on images.
These patients were different, thus leaving 98 unique
patients for analysis comparing responses between Surgeon
#1 and Surgeon #2.
When comparing technical feasibility for sublobar
resection, there was moderate interrater agreement (κ=0.414).
For wedge resection feasibility, interrater agreement was
slightly higher (κ=0.473). For segmentectomy, the interrater
agreement was fair (κ=0.225).
When examining reported reasons against wedge
resection, there was moderate interrater agreement (κ=0.431).
However, for reasons against segmentectomy, there was only
slight agreement (κ=0.052). See Table 1.
Discussion

Figure 2 Thoracic surgeon survey with sample image.

to sublobar resection. Of these, 58 (84%) had the option
of wedge resection as feasible while 42 (62.3%) were
considered feasible for segmentectomy. When prompted
for reasons against a sublobar resection, at times Surgeon
#2 provided multiple responses (e.g., ‘A’ and ‘B’), with
10 patients (24 responses) for wedge resection and
14 patients (29 responses) for segmentectomy, so all of these
were reported. The most common reason against wedge
resection for Surgeon #2 was also “depth of tumor in lung”
for 32 patients (80%). The most common reason against
© Journal of Thoracic Disease. All rights reserved.

Our results suggest that approximately 30–35% of patients
who are able to receive SBRT are not able to undergo
sublobar resection, based on technical considerations
from pretreatment diagnostic imaging. This represents
a subpopulation of early stage NSCLC patients that is
often overlooked in the current treatment paradigm. The
proportion of patients deemed eligible for wedge resection
(~60%) was higher than segmentectomy (~40%), with
moderate to fair interrater agreement. Agreement on
reasons against segmentectomy was also relatively lower
than that on wedge resection.
Although lobectomy is the standard of care for medically
operable patients (10), there exists a subset of patients in
whom sublobar resection may be considered. The NCCN
guidelines define this as patients with poor pulmonary
reserve, major comorbidities, and/or peripheral nodule
≤2 cm in size with ≥50% ground-glass appearance or long
doubling time (1). These same patients are oftentimes also
eligible for SBRT as it is felt that SBRT has minimal risks
associated with treatment of such patients with resulting
stable pulmonary function post-treatment. Additionally,
more recent studies have shown that sublobar resection
can be comparable to lobectomy for clinical outcomes
after adjusting for confounders and also factoring in
J Thorac Dis 2021;13(3):1576-1583 | http://dx.doi.org/10.21037/jtd-20-2001
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A

Reasons against segmentectomy

Surgeon #1
Surgeon #2

44

23
12

23

9

7
3
A

B

1

B

C

D

Reasons against wedge resection

4
0
E
Surgeon #1
Surgeon #2

32

22

12
8
5

4

A

B

C

3

1

D

0 1
E

Figure 3 Individual surgeon survey responses. (A) A, the tumor is not clearly confined to one segment; B, inadequate margin due to tumor
size; C, inadequate margin due to tumor location; D, segmental anatomy is not clear on imaging; E, other (free-form response). Surgeon
#2 provided multiple responses for some patients, thus these have all been compiled leading to more than 55 responses (total 70). (B) A, the
tumor is too deep within the lung; B, inadequate margin due to tumor size; C, inadequate margin due to tumor location; D, the tumor is
too small to be palpable; E, other (free-form response). Surgeon #2 provided multiple responses for some patients, thus these have all been
compiled leading to more than 40 responses (total 54).

Table 1 Interrater agreement analysis
Technical feasibility Kappa coefficient (κ) Magnitude

P value

Sublobar resection

0.414

Moderate

<0.001

Wedge resection

0.473

Moderate

<0.001

Segmentectomy

0.225

Fair

0.027

Reasons against
wedge resection

0.431

Moderate

0.001

Reasons against
segmentectomy

0.052

Slight

0.331

size and location of lesions while preserving pulmonary
function (7,11-15). An earlier meta-analysis of stage I
NSCLC patients showed no overall survival differences
between these surgical techniques at 1, 3, and 5 years
with a subsequent, separate meta-analysis also showing no
differences in disease-free and overall survival for patients

© Journal of Thoracic Disease. All rights reserved.

intentionally selected for sublobar resection when compared
to their lobectomy counterparts with small, peripheral
lesions (6,12). SBRT has also been evaluated for early stage
peripheral lesions in medically operable patients in the
setting of a single-arm phase II clinical trial, RTOG 0618,
with 26 patients evaluated and achieving relatively high local
control (96%) and low rates of surgical salvage and adverse
events while preserving pulmonary function (16). SBRT
is also more cost-effective for marginally operable stage I
NSCLC patients when compared to either wedge resection
or lobectomy (17). Markov modeling of medically operable
patients stratified by smoking history suggested SBRT was
also similar to surgery when comparing quality-adjusted
life years (QALY) (18). Through a propensity scorematched analysis of National Cancer Database, an increased
mortality risk associated with more extensive surgery and
older age were found when compared to SBRT. Although
SBRT has been traditionally associated with treatment of
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peripheral lung lesions due to early experiences with excess
toxicity for centrally located tumors (19), our improved
understanding for dosing and constraints for organs at risk
has led to more patients with centrally located tumors to
now be eligible for SBRT. A recent phase I/II study, RTOG
0813, determined that central tumors could be treated
comparably to peripheral tumors with a MTD of 12 Gy per
fraction (20). In recent years, the national trend away from
lobectomy and towards sublobar resection and SBRT makes
these findings more pertinent (21). Therefore, we believe
that our comparison of these two treatment modalities is
important for being taken into consideration for managing
a subpopulation of early stage NSLC patients.
Our study is limited to two board certified thoracic
surgeons and could be further improved with additional
participation. In addition, while our study does analyze
strengths of interrater agreement, we lack intrarater
reliability. The latter could provide additional insights
on the consistency of assessment for which lesions are
deemed resectable by an individual. External validation of
the customized survey will introduce additional data for
interrater agreement analysis.
Although our surgeons had moderate interrater
agreement regarding ineligibility for wedge resection
and corresponding reasons against wedge resection, the
interrater agreement for segmentectomy was relatively
lower with fair interrater agreement for ineligibility and
even lower for the reasons against segmentectomy. This
is an interesting finding, as segmentectomy is a more
complex procedure than wedge resection, with the latter
a nonanatomic resection. This disparity is likely multifactorial, including surgeon-specific training, experience
and preferential practice as well as patient anatomies and
tumor location, size, and appearance.
Current practice guidelines for early stage NSCLC
are available from several organizations, including the
American Society for Radiation Oncology, European Society
for Medical Oncology, National Comprehensive Cancer
Network, and Spanish Society of Medical Oncology. These
guidelines tend to favor lobectomy, followed by sublobar
resection, and lastly by SBRT (1,22-24). For medically
operable patients, SBRT is recommended against unless
in the setting of a clinical trial. Part of this rationale is that
surgery can provide additional nodal pathology for staging
purposes so that there remains the risk of under-staging due
to occult disease, with PET/CT scans having a false-negative
rate approximately 10–15% for clinical stage I disease
(25-27). However, a meta-analysis of over 1,000 patients

© Journal of Thoracic Disease. All rights reserved.
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from 10 studies, examined the negative predictive value of
PET/CT and found NPV as high as 94% for mediastinal
metastases for T1 disease (28). Therefore, we believe
that for some early stage NSCLC patients who are not
resectable candidates or who will elect to decline surgery,
the benefits from invasive nodal staging should be balanced
by the risks and costs associated with such a strategy. There
are several options for mediastinal staging, including no
invasive mediastinal staging, endobronchial ultrasoundguided transbronchial needle aspiration (EBUS-TBNA), and
mediastinoscopy. When comparing these options for QALY
in a single payer system, there were relatively small realworld disparities between these modalities (5.80 vs. 5.87 vs.
5.86 QALYs, respectively), resulting in approximately 3–3.5
weeks’ difference of optimal health (29). When comparing
the incremental cost-effectiveness ratios (ICER) for these
mediastinal staging options, for cN0 patients with low risk
(<2.5%) of pN2 involvement, invasive mediastinal staging
is not cost-effective with a ICER of ~$20,016.68/QALY for
EBUS-TBNA alone and ~$1,076,163.63/QALY for EBUSTBNA with mediastinoscopy. In addition, we should also
consider the operative mortality associated with surgical
resection, ranging from 1.1% for wedge resection, 1.8%
for segmentectomy, and 2.0% for lobectomy patients (30).
These elements should be factored in the decision-making
process when managing early stage NSCLC patients,
especially for those who may be borderline medically
operable or are not optimal candidates for resectability.
Clinical trials attempting to compare surgery and SBRT
have faced barriers with accrual and questions of equipoise
(3,31). Ongoing phase III trials, such as the VALOR trial (32)
comparing lobectomy or segmentectomy with mediastinal
lymph node sampling (adjuvant chemotherapy for positive
lymph nodes) vs SBRT and the SABRTOOTHv1 trial (33) in
the UK which compares sublobar resection +/− intraoperative
brachytherapy vs. SBRT, will help elucidate the value of SBRT
in medically operable patients in the setting of anatomic and
nonanatomic resections as well as utility of brachytherapy with
sublobar resection. Future clinical trials hoping to compare
these treatment modalities may take into consideration that a
subpopulation of patients will be considered medically operable
but are ineligible for sublobar resection due to technical
reasons, which will affect screening and potential enrollment
success. In addition, we believe that prior clinical trials would
have excluded such patients from enrollment and analysis,
which could lead to a bias in patient selection and ultimately
affecting the outcomes of comparing these modalities.
Our study is the first of its kind to report a quantifiable
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estimate on the proportion of early stage NSCLC patients
who are treatable with SBRT, but are not appropriate for
sublobar resection based on technical criteria. Results from
prior clinical trials may need to be qualified by extrapolating
outcomes only to patients who are both medically and
technically operable. This specific subpopulation of patients
should be considered when developing practice guidelines
for care in early stage NSCLC patients as well as for
designing eligibility criteria and screening for clinical trials
comparing sublobar resection with SBRT.
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